The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
Open accessAbstract
The use of nanotechnology in medicine has the potential to have a major impact on human health for the prevention, diagnosis, and treatment of diseases. One particular aspect of the nanomedicine field which has received a great deal of attention is the design and development of nanoparticulate nanomedicines (NNMs) for drug delivery (i.e., drug-containing nanoparticles). NNMs are intended to deliver drugs via various mechanisms: solubilization, passive targeting, active targeting, and triggered release. The NNM approach aims to increase therapeutic efficacy, decrease the therapeutically effective dose, and/or reduce the risk of systemic side effects. In order to move a NNM from the bench to the bedside, several experimental challenges need to be addressed. This review will discuss the current trends and challenges in the clinical translation of NNMs as well as the potential pathways for translational development and commercialization. Key issues related to the clinical development of NNMs will be covered, including biological challenges, large-scale manufacturing, biocompatibility and safety, intellectual property (IP), government regulations, and overall cost-effectiveness in comparison to current therapies. These factors can impose significant hurdles limiting the appearance of NNMs on the market, irrelevant of whether they are therapeutically beneficial or not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 2×
“Potential reasons for this discrepancy have previously been reviewed (Sawant and Torchilin, 2012; Allen and Cullis, 2013), and include factors such as target accessibility and expression, disease-dependent anatomical and physiological barriers, and formulation stability.”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Self-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Self-citationNanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citationMaeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Needham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Fate and behavior of liposomes in vivo: a review of controlling factors.
Senior, J. H. (1987) · PubMed · Cited by 591
Nel, A., Xia, T., Meng, H., Wang, X., Lin, S., Ji, Z., & Zhang, H. (2013) · Accounts of Chemical Research · doi:10.1021/ar300022h · Cited by 579
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Hua, S., Marks, E., Schneider, J. J., & Keely, S. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.02.018 · Cited by 494
Self-citationNoninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects
Kunjachan, S., Ehling, J., Storm, G., Kiessling, F., & Lammers, T. (2015) · Chemical Reviews · doi:10.1021/cr500314d · Cited by 480
Self-citationPhospholipid spherules (liposomes) as a model for biological membranes
Sessa, G., & Weissmann, G. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43097-4 · Cited by 446
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Self-citationLyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Self-citationEnzyme entrapment in liposomes
Gregoriadis, G., Leathwood, P. D., & Ryman, B. E. (1971) · FEBS Letters · doi:10.1016/0014-5793(71)80109-6 · Cited by 331
Effects of engineered nanoparticles on the innate immune system
Liu, Y., Hardie, J., Zhang, X., & Rotello, V. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.011 · Cited by 315
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 309
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304
Thermosensitive polymer-modified liposomes
Kono, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00204-6 · Cited by 303
Metselaar, J. M., Wauben, M. H. M., Wagenaar‐Hilbers, J. P. A., Boerman, O. C., & Storm, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11140 · Cited by 302
Self-citationNanotherapeutics in the EU: an overview on current state and future directions
Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s55359 · Cited by 294
Forssen, E., & Willis, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00083-5 · Cited by 287
Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases
Gregoriadis, G., & Ryman, B. E. (1971) · Biochemical Journal · doi:10.1042/bj1240058p · Cited by 286
The use of lipid-based nanocarriers for targeted pain therapies
Hua, S., & Wu, S. Y. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00143 · Cited by 268
Self-citationAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
Safety assessment of nanomaterials: Implications for nanomedicine
Nyström, A. M., & Fadeel, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.027 · Cited by 264
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Self-citationNanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
Greish, K., Nehoff, H., Parayath, N., Domanovitch, L., & Taurin, S. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s47129 · Cited by 238
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232
Nanotechnology and Nanomedicine: Going Small Means Aiming Big
Kumar Teli, M., Mutalik, S., & Rajanikant, G. K. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208992 · Cited by 177
Clinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 175
Immunoliposomes for the targeted delivery of antitumor drugs
Mastrobattista, E., Koning, G. A., & Storm, G. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00043-5 · Cited by 172
Self-citationTranslational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 155
Capture of Stealth Nanoparticles by the Body’s Defences
Moghimi, S. M., & Hunter, A. C. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i6.30 · Cited by 154
Metselaar, J. M., van den Berg, W. B., Holthuysen, A. E. M., Wauben, M. H. M., Storm, G., & van Lent, P. L. E. M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009944 · Cited by 148
Self-citationDefining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?
Satalkar, P. P., Elger, B. S., & Shaw, D. (2015) · Science and Engineering Ethics · doi:10.1007/s11948-015-9705-6 · Cited by 143
Oomen, A. G., Bos, P. M. J., Fernandes, T. F., Hund‐Rinke, K., Boraschi, D., Byrne, H. J., Aschberger, K., Gottardo, S., von der Kammer, F., Kühnel, D., et al. (2013) · Nanotoxicology · doi:10.3109/17435390.2013.802387 · Cited by 138
Chapter 4 Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells
Poste, G. H., Papahadjopoulos, D., & Vail, W. J. (1976) · Methods in cell biology · doi:10.1016/s0091-679x(08)60468-9 · Cited by 133
From “Banghasomes” to liposomes: A memoir of Alec Bangham, 1921–2010
Deamer, D. W. (2010) · The FASEB Journal · doi:10.1096/fj.10-0503 · Cited by 129
Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions
Szebeni, J., & Moghimi, S. M. (2009) · Journal of Liposome Research · doi:10.1080/08982100902792855 · Cited by 128
Gaspar, R. S. (2007) · Nanomedicine · doi:10.2217/17435889.2.2.143 · Cited by 124
Narang, A., Chang, R.-K., & Hussain, M. A. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23691 · Cited by 122
Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies
Jang, B., Kwon, H., Katila, P., Lee, S. J., & Lee, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.023 · Cited by 114
Hua, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00127 · Cited by 113
Self-citationMauro Ferrari, B. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.06.001 · Cited by 113
Szebeni, J., & Storm, G. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.177 · Cited by 111
Self-citationBawa, R. (2007) · Nanomedicine · doi:10.2217/17435889.2.3.351 · Cited by 108
Accomasso, L., Cristallini, C., & Giachino, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00228 · Cited by 103
Drug targeting systems for inflammatory disease: One for all, all for one
Crielaard, B. J., Lammers, T., Schiffelers, R. M., & Storm, G. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.014 · Cited by 101
Self-citationTheek, B., Gremse, F., Kunjachan, S., Fokong, S., Pola, R., Pechar, M., Deckers, R., Storm, G., Ehling, J., Kiessling, F. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.007 · Cited by 100
Self-citationDušinská, M., Boland, S., Saunders, M., Juillerat‐Jeanneret, L., Tran, L., Pojana, G., Marcomini, A., Volkovová, K., Tulinská, J., Knudsen, L. E., et al. (2015) · Nanotoxicology · doi:10.3109/17435390.2014.991431 · Cited by 99
Nanoparticulate carriers for the treatment of coronary restenosis.
Brito, L., & Amiji, M. M. (2007) · PubMed Central · Cited by 99
Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis
Maiseyeu, A., Mihai, G., Kampfrath, T., Simonetti, O. P., Sen, C. K., Roy, S., Rajagopalan, S., & Parthasarathy, S. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800405-jlr200 · Cited by 95
SMART drug delivery systems: Back to the future vs. clinical reality
Lammers, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.046 · Cited by 80
Strategies for triggered drug release from tumor targeted liposomes
Blenke, E. O., Mastrobattista, E., & Schiffelers, R. M. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.805742 · Cited by 80
Lipid-based carriers: manufacturing and applications for pulmonary route
Jaafar‐Maalej, C., Elaïssari, A., & Fessi, H. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.702751 · Cited by 78
The drug delivery field at the inflection point: Time to fight its way out of the egg
Park, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.030 · Cited by 72
Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?
Diab, R., Jaafar‐Maalej, C., Fessi, H., & Maincent, P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9377-y · Cited by 68
Jackman, J. A., Mészáros, T., Fülöp, T., Urbanics, R., Szebeni, J., & Cho, N. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.377 · Cited by 66
Storm, G., ten Kate, M. T., Working, P. K., & Bakker‐Woudenberg, I. A. J. M. (1998) · PubMed · Cited by 64
Self-citationHua, S. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/e199 · Cited by 63
Self-citationNanotechnology in diagnostics and therapeutics for gastrointestinal disorders
Laroui, H., Rakhya, P., Xiao, B., Viennois, E., & Merlin, D. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.03.019 · Cited by 61
Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies
Shajari, N., Mansoori, B., Davudian, S., Mohammadi, A., & Baradaran, B. (2016) · Current Drug Delivery · doi:10.2174/1567201813666160816105408 · Cited by 60
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases
Talekar, M., Tran, T.-H., & Amiji, M. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9772-2 · Cited by 53
Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation
Coimbra, M., Banciu, M., Fens, M. H. A. M., Smet, L. D., Cabaj, M., Metselaar, J. M., Storm, G., & Schiffelers, R. M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.09.011 · Cited by 52
Self-citationHua, S., & Cabot, P. J. (2013) · PubMed · Cited by 51
Self-citationCalcagno, C., Lobatto, M. E., Dyvorne, H., Robson, P. M., Millon, A., Senders, M. L., Lairez, O., Ramachandran, S., Coolen, B. F., Black, A. T., et al. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3369 · Cited by 42
Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy
Mishra, D. K., Balekar, N., & Mishra, P. K. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0352-5 · Cited by 38
Larsson, M., Huang, W.-T., Liu, D., & Lošić, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.004 · Cited by 33
Barz, M., Luxenhofer, R., & Schillmeier, M. (2015) · Nanomedicine · doi:10.2217/nnm.15.156 · Cited by 31
Kim, M., & Williams, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018764923 · Cited by 22
A new prize system for drug innovation
Gandjour, A., & Chernyak, N. (2011) · Health Policy · doi:10.1016/j.healthpol.2011.06.001 · Cited by 17
Nanomedicine?, Q. V., Luxenhofer, R., Barz, M., & Schillmeier, M. (2014) · Nanomedicine · doi:10.2217/nnm.14.140 · Cited by 12
Liposomes targeting tumour stromal cells
Kuijpers, S. A., Coimbra, M., Storm, G., & Schiffelers, R. M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.522204 · Cited by 11
Self-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Green Synthesis of Metallic Nanoparticles: Applications and Limitations
Dikshit, P., Kumar, J., Das, A., Sadhu, S., Sharma, S., Singh, S., Gupta, P., & Kim, B. (2021) · Catalysts · doi:10.3390/catal11080902 · Cited by 882
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Metadata
- Authors
- Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-17
- Volume
- 9
- Pages
- 790-790
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2810420630
- Cited by
- 1,048
- References
- 102
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.